MA29722B1 - Schema posologique pour le prasugrel - Google Patents

Schema posologique pour le prasugrel

Info

Publication number
MA29722B1
MA29722B1 MA30577A MA30577A MA29722B1 MA 29722 B1 MA29722 B1 MA 29722B1 MA 30577 A MA30577 A MA 30577A MA 30577 A MA30577 A MA 30577A MA 29722 B1 MA29722 B1 MA 29722B1
Authority
MA
Morocco
Prior art keywords
prasugrel
dosage
dosage scheme
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA30577A
Other languages
English (en)
Inventor
John Thomas Brandt
Nagy Alphonse Farid
Joseph Anthony Jakubowski
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29722B1 publication Critical patent/MA29722B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'INVENTION CONCERNE UNE POSOLOGIE POUR TRAITER UNE MALADIE VASCULAIRE CHEZ UN HUMAIN, CETTE POSOLOGIE CONSISTANT À ADMINISTRER UN DOSE DE CHARGE D'ENVIRON 30 MG À 70 MG DE PRASUGREL OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET À ADMINISTRER ENSUITE QUOTIDIENNEMENT ENVIRON 7.5 MG À 15 MG COMME DOSE D'ENTRETIEN DE PRASUGREL OU D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI.
MA30577A 2005-06-17 2008-01-16 Schema posologique pour le prasugrel MA29722B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
MA29722B1 true MA29722B1 (fr) 2008-09-01

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30577A MA29722B1 (fr) 2005-06-17 2008-01-16 Schema posologique pour le prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (fr)
EP (1) EP1893205A4 (fr)
JP (1) JP2008543853A (fr)
KR (1) KR20080016647A (fr)
CN (1) CN101198329A (fr)
AU (1) AU2006259538A1 (fr)
BR (1) BRPI0612624A2 (fr)
CA (1) CA2612315A1 (fr)
EA (1) EA200800075A1 (fr)
EC (1) ECSP078014A (fr)
GT (1) GT200600263A (fr)
IL (1) IL187486A0 (fr)
MA (1) MA29722B1 (fr)
MX (1) MX2007015430A (fr)
NO (1) NO20080244L (fr)
TN (1) TNSN07474A1 (fr)
WO (1) WO2006138317A2 (fr)
ZA (1) ZA200710769B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5274261B2 (ja) 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
EP2100607A4 (fr) * 2006-12-07 2010-01-06 Daiichi Sankyo Co Ltd Composition pharmaceutique présentant une stabilité au stockage améliorée
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
WO2010132711A1 (fr) 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Compositions pharmaceutiques comprenant des dérivés de prasugrel et de cyclodextrine, leurs procédés de préparation et méthodes d'utilisation
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2409685A3 (fr) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prasugrel à désintégration orale
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP3106151A1 (fr) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Compositions pharmaceutiques de bromhydrate de prasugrel
WO2018167447A1 (fr) * 2017-03-14 2018-09-20 University Of Sheffield Aspirine à faible dose (1-50 mg) conjointement avec des antiagrégants plaquettaires de type ticagrelor d'anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
ATE398624T1 (de) * 2000-07-06 2008-07-15 Daiichi Sankyo Co Ltd Säure-additionssalze von hydropyridinderivaten
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
NZ526540A (en) * 2000-12-25 2004-11-26 Sankyo Co Medicinal compositions containing aspirin and 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine useful in preventing thrombus or embolus diseases
JP2006525328A (ja) * 2003-05-05 2006-11-09 イーライ リリー アンド カンパニー 心疾患の治療方法

Also Published As

Publication number Publication date
AU2006259538A1 (en) 2006-12-28
IL187486A0 (en) 2008-06-05
US20090156632A1 (en) 2009-06-18
CA2612315A1 (fr) 2006-12-28
ZA200710769B (en) 2009-09-30
EP1893205A2 (fr) 2008-03-05
CN101198329A (zh) 2008-06-11
TNSN07474A1 (en) 2009-03-17
KR20080016647A (ko) 2008-02-21
ECSP078014A (es) 2008-01-23
MX2007015430A (es) 2008-02-21
WO2006138317A2 (fr) 2006-12-28
GT200600263A (es) 2007-02-23
EP1893205A4 (fr) 2010-06-30
NO20080244L (no) 2008-01-14
WO2006138317A3 (fr) 2007-05-03
JP2008543853A (ja) 2008-12-04
BRPI0612624A2 (pt) 2016-11-29
EA200800075A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
MA29722B1 (fr) Schema posologique pour le prasugrel
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL189546A0 (en) Therapy for the treatment of disease
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NZ572049A (en) Method for treatment of constipation-predominant irritable bowel syndrome
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
WO2007053661A3 (fr) Utilisations d'anticorps anti-cd40
EP2331095A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2009039397A3 (fr) Amides substitués, procédé pour les préparer et procédé pour les utiliser
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2007087151A3 (fr) Méthode de traitement d'un dysfonctionnement cognitif
DE602004011394D1 (en) Thiazolderivate
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2008030830A3 (fr) Composition à libération prolongée et son procédé d'utilisation
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
TW200616644A (en) Medicine for prevention or treatment of diabetes
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.